TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Immigrant Families: Working Together To Move More and To Eat Well
Brief Summary: This project will broadly explore the efficacy of community participation in the design and implementation of an intervention to improve physical activity and nutrition among immigrant and refugee (Hispanic, Somali, Sudanese, Cambodian) families in Rochester, Minnesota


Options:
A: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
B: Arm Label: Tools for Teen Moms Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tools for Teen Moms | Arm Label: MIHP standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tools for Teen Moms; Assigned to Arm(s): Tools for Teen Moms Intervention Group
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face family mentoring and education sessions, Behavioral: Telephone follow-up | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face family mentoring and education sessions; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Telephone follow-up; Assigned to Arm(s): Intervention Group
D: Arm Label: Healthy Buddies Curriculum; Type: EXPERIMENTAL; Interventions: Other: Healthy Buddies Curriculum | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Buddies Curriculum; Assigned to Arm(s): Healthy Buddies Curriculum

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Immigrant Families: Working Together To Move More and To Eat Well
Brief Summary: This project will broadly explore the efficacy of community participation in the design and implementation of an intervention to improve physical activity and nutrition among immigrant and refugee (Hispanic, Somali, Sudanese, Cambodian) families in Rochester, Minnesota


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Experimental | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Experimental; Assigned to Arm(s): 1
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face family mentoring and education sessions, Behavioral: Telephone follow-up | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face family mentoring and education sessions; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Telephone follow-up; Assigned to Arm(s): Intervention Group
C: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Challenge! | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Challenge!; Assigned to Arm(s): Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Therapeutic Option for Hepatitis B and C: a French Cohort
Brief Summary: * The cohort will integrate clinical, genetic, pharmacogenomics, environmental, biomarkers and behavioral data in a large number of patients and will be a leading equipment for crossdisciplinary and translational research on hepatitis.
* The cohort will be the main support for estimating the relative effects of treatments and for further cost-effectiveness studies on the management and treatment options in chronic HCV (Hepatitis C Virus)and HBV (Hepatitis B virus)infections.


Options:
A: Arm Label: Peginterferon alfa-2a and ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a and ribavirin | Arm Label: Peginterferon alfa-2a; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a | Intervention Type: DRUG; Name: Peginterferon alfa-2a and ribavirin; Assigned to Arm(s): Peginterferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): Peginterferon alfa-2a
B: Arm Label: Immediate Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: Deferred Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Grazoprevir, Drug: Placebo to Elbasvir | Arm Label: Intensive PK; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Placebo to Grazoprevir; Assigned to Arm(s): Deferred Treatment | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): Deferred Treatment
C: Arm Label: hepatitis C and/or B; Type: N/A; Interventions: N/A
D: Arm Label: ABT-493/ABT-530; Type: EXPERIMENTAL; Interventions: Drug: ABT-493/ABT-530 | Intervention Type: DRUG; Name: ABT-493/ABT-530; Assigned to Arm(s): ABT-493/ABT-530

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Fitness Training in Subacute Stroke (PHYS-Stroke)
Brief Summary: The aim of this study is to investigate whether a 4-week physical fitness training (target intervention) in stroke patients (subacute stage) increase the walking speed and activities of daily living compared with a control intervention (relaxation exercises). The target or control intervention is performed in addition to standard rehabilitation treatment.


Options:
A: Arm Label: STUFFS; Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behaviour intervention | Intervention Type: BEHAVIORAL; Name: Sedentary behaviour intervention; Assigned to Arm(s): STUFFS
B: Arm Label: Dual-task gait training; Type: EXPERIMENTAL; Interventions: Behavioral: Gait training | Arm Label: Single-task gait training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Gait training | Intervention Type: BEHAVIORAL; Name: Gait training; Assigned to Arm(s): Dual-task gait training, Single-task gait training
C: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
D: Arm Label: physical fitness training; Type: EXPERIMENTAL; Interventions: Procedure: physical fitness training | Arm Label: relaxation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: relaxation | Intervention Type: PROCEDURE; Name: physical fitness training; Assigned to Arm(s): physical fitness training | Intervention Type: PROCEDURE; Name: relaxation; Assigned to Arm(s): relaxation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Fitness Training in Subacute Stroke (PHYS-Stroke)
Brief Summary: The aim of this study is to investigate whether a 4-week physical fitness training (target intervention) in stroke patients (subacute stage) increase the walking speed and activities of daily living compared with a control intervention (relaxation exercises). The target or control intervention is performed in addition to standard rehabilitation treatment.


Options:
A: Arm Label: Exercise recommendation; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise, Exercise recommendation
B: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Arm 1: Yoga Group; Type: EXPERIMENTAL; Interventions: Other: Yoga focused on strength, flexibility, and balance | Arm Label: Arm 2: Yoga Group Plus; Type: EXPERIMENTAL; Interventions: Other: Yoga focused on strength, flexibility, and balance | Arm Label: Arm 3: Wait list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga focused on strength, flexibility, and balance; Assigned to Arm(s): Arm 1: Yoga Group, Arm 2: Yoga Group Plus
D: Arm Label: physical fitness training; Type: EXPERIMENTAL; Interventions: Procedure: physical fitness training | Arm Label: relaxation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: relaxation | Intervention Type: PROCEDURE; Name: physical fitness training; Assigned to Arm(s): physical fitness training | Intervention Type: PROCEDURE; Name: relaxation; Assigned to Arm(s): relaxation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis
Brief Summary: The purpose of this study is to evaluate the therapeutic response to fluconazole in patients with cutaneous leishmaniasis caused by and L.(V.)guyanensis and L.(V.) braziliensis.


Options:
A: Arm Label: Miltefosine; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine | Arm Label: Glucantime®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucantime® | Arm Label: Thermotherapy; Type: EXPERIMENTAL; Interventions: Device: Thermotherapy | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Miltefosine | Intervention Type: DEVICE; Name: Thermotherapy; Assigned to Arm(s): Thermotherapy | Intervention Type: DRUG; Name: Glucantime®; Assigned to Arm(s): Glucantime®
B: Arm Label: Fluconazole; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole | Arm Label: Meglumine Antimoniate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine Antimoniate | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Fluconazole | Intervention Type: DRUG; Name: Meglumine Antimoniate; Assigned to Arm(s): Meglumine Antimoniate
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miltefosine | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Meglumine antimoniate; Assigned to Arm(s): Group 2
D: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Improvements With Minute Ventilation-targeted ASV Therapy in Heart Failure (CAT-HF)
Brief Summary: The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.


Options:
A: Arm Label: ASV mode; Type: ACTIVE_COMPARATOR; Interventions: Device: VPAP Adapt SV | Arm Label: CPAP mode; Type: ACTIVE_COMPARATOR; Interventions: Device: VPAP Adapt SV | Intervention Type: DEVICE; Name: VPAP Adapt SV; Assigned to Arm(s): ASV mode, CPAP mode
B: Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Europe: AutoSet CS (USA: VPAP Adapt SV) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Europe: AutoSet CS (USA: VPAP Adapt SV); Assigned to Arm(s): Treatment Group
C: Arm Label: Nocturnal oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Nocturnal oxygen | Arm Label: Adaptive servo ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Adaptive servo ventilation | Intervention Type: DEVICE; Name: Adaptive servo ventilation; Assigned to Arm(s): Adaptive servo ventilation | Intervention Type: DEVICE; Name: Nocturnal oxygen; Assigned to Arm(s): Nocturnal oxygen therapy
D: Arm Label: MV ASV+OMT; Type: EXPERIMENTAL; Interventions: Device: MV ASV, Drug: Optimized Medical Treatment | Arm Label: OMT only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimized Medical Treatment | Intervention Type: DEVICE; Name: MV ASV; Assigned to Arm(s): MV ASV+OMT | Intervention Type: DRUG; Name: Optimized Medical Treatment; Assigned to Arm(s): MV ASV+OMT, OMT only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Improvements With Minute Ventilation-targeted ASV Therapy in Heart Failure (CAT-HF)
Brief Summary: The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.


Options:
A: Arm Label: positive airway pressure; Type: EXPERIMENTAL; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): positive airway pressure
B: Arm Label: Nocturnal oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Nocturnal oxygen | Arm Label: Adaptive servo ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Adaptive servo ventilation | Intervention Type: DEVICE; Name: Adaptive servo ventilation; Assigned to Arm(s): Adaptive servo ventilation | Intervention Type: DEVICE; Name: Nocturnal oxygen; Assigned to Arm(s): Nocturnal oxygen therapy
C: Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Europe: AutoSet CS (USA: VPAP Adapt SV) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Europe: AutoSet CS (USA: VPAP Adapt SV); Assigned to Arm(s): Treatment Group
D: Arm Label: MV ASV+OMT; Type: EXPERIMENTAL; Interventions: Device: MV ASV, Drug: Optimized Medical Treatment | Arm Label: OMT only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimized Medical Treatment | Intervention Type: DEVICE; Name: MV ASV; Assigned to Arm(s): MV ASV+OMT | Intervention Type: DRUG; Name: Optimized Medical Treatment; Assigned to Arm(s): MV ASV+OMT, OMT only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen as Adjuvant, Postoperative Pain After Herniated Disc Surgery
Brief Summary: The analgesic effect of dexamethasone is not well described, but studies have shown that dexamethasone can be a safe part of a multimodal analgesic strategy after surgery. Our purpose is to investigate if dexamethasone in combination with paracetamol and ibuprofen has an increased analgesic effect compared to paracetamol and ibuprofen alone, on postoperative pain after spine surgery. Our hypothesis is that dexamethasone can reduce postoperative pain and reduce opioidconsumption and side effects compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A
D: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: When and How to Administer Oxytocin for Active Management of Third Stage of Labour
Brief Summary: To compare the efficacy of the route and timing of oxytocin administration for Active management of third stage of labour (AMTSL).


Options:
A: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
B: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
C: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: When and How to Administer Oxytocin for Active Management of Third Stage of Labour
Brief Summary: To compare the efficacy of the route and timing of oxytocin administration for Active management of third stage of labour (AMTSL).


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
C: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
D: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: When and How to Administer Oxytocin for Active Management of Third Stage of Labour
Brief Summary: To compare the efficacy of the route and timing of oxytocin administration for Active management of third stage of labour (AMTSL).


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
B: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin
C: Arm Label: Saline group; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Saline group
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: B